Spero Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Spero Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- SPRO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001701108
Board of directors
-
Ankit Mahadevia · Director · CEO and PresidentSince 2023
- Since 2023
-
Frank E. Thomas · DirectorSince 2023
-
John C. Pottage Jr. · DirectorSince 2023
-
Kathleen Tregoning · DirectorSince 2023
-
Milind Deshpande · DirectorSince 2023
-
Patrick V.j.j. Vink · DirectorSince 2023
-
Sath Shukla · Director · CEO and PresidentSince 2023
-
Scott Thomas Jackson · DirectorSince 2023
Chief executives
Ankit Mahadevia
· CEO and President
Dates unknown
Sath Shukla
· CEO and President
Dates unknown
Board connections
4 of this board's directors also sit on 8 other boards.
- via Cynthia Smith
- via Cynthia Smith
- via Kathleen Tregoning
- via Scott Thomas Jackson
- via Frank E. Thomas
- via Scott Thomas Jackson
- via Cynthia Smith
- via Cynthia Smith
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $552,042
- 9 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 3, 2026 | Zack Debra Officer (Chief Medical Officer) | Grant or award | +162,311 | — | — |
| Jun 23, 2026 | Milind Deshpande Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Kathleen Tregoning Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Cynthia Smith Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Patrick V.j.j. Vink Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Frank E. Thomas Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | Scott Thomas Jackson Director | Grant or award | +10,000 | — | — |
| Jun 23, 2026 | John C. Pottage Jr. Director | Grant or award | +10,000 | — | — |
| May 4, 2026 | Rajavelu Esther Officer (See Remarks) | Open-market sale | −25,240 | $2.51 | $63,352 |
| Feb 6, 2026 | Rajavelu Esther Officer (See Remarks) | Open-market sale | −37,101 | $2.36 | $87,558 |
| Feb 6, 2026 | Keutzer Timothy Officer (Chief Operating Officer) | Open-market sale | −18,652 | $2.36 | $44,019 |
| Feb 6, 2026 | Rajavelu Esther Officer (See Remarks) | Open-market sale | −50,816 | $2.36 | $119,926 |
| Feb 4, 2026 | Keutzer Timothy Officer (Chief Operating Officer) | Open-market sale | −3,471 | $2.24 | $7,775 |
| Feb 3, 2026 | Keutzer Timothy Officer (Chief Operating Officer) | Open-market sale | −24,224 | $2.14 | $51,839 |
| Feb 2, 2026 | Keutzer Timothy Officer (Chief Operating Officer) | Grant or award | +68,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.